恒瑞医药：注射用SHR-A1904纳入突破性治疗品种名单

Core Viewpoint - Heng Rui Medicine (600276.SH) has announced that its injectable SHR-A1904 has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center, targeting CLDN18.2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after at least one line of systemic therapy [1] Group 1 - The company and its subsidiary, Shanghai Heng Rui Medicine Co., Ltd., are advancing their drug development with SHR-A1904 being recognized as a breakthrough therapy [1] - The targeted indication for SHR-A1904 is for patients with CLDN18.2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma [1] - The inclusion in the breakthrough therapy list may expedite the development and approval process for SHR-A1904, potentially enhancing the company's market position [1]